Real-world Analyses of Patients With Elevated Atherosclerotic Cardiovascular Disease Risk From the Optum Research Database

References

• Kochanek KD , MurphySL, XuJ, AriasE. Deaths: final data for 2017. Natl Vital Stat. Rep., 68(9), 1–75 (2019).
   Google Scholar
• Global Burden of Disease Study Investigators . Global, regional and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet, 392(10159), 1736–1788 (2018).
   PubMed Web of Science ®Google Scholar
• Arnett DK , BlumenthalRS, AlbertMAet al. 2019 ACC/AHA guideline on the primary prevention of cardiovascular disease: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation, 140(11), e596–e646 (2019).
   PubMed Web of Science ®Google Scholar
• Virani SS , AlonsoA, BenjaminEJet al. Heart disease and stroke statistics-2020 update: a report from the American Heart Association. Circulation, 141(9), e139–e596 (2020).
   PubMed Web of Science ®Google Scholar
• Stone NJ , RobinsonJ, LichtensteinAHet al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation, 129(2 Suppl. 25), S1–S45 (2014).
   PubMed Web of Science ®Google Scholar
• Miller M , CannonCP, MurphySA, QinJ, RayKK, BraunwaldE. Impact of triglyceride levels beyond low-density lipoprotein cholesterol after acute coronary syndrome in the PROVE IT-TIMI 22 trial. J. Am. Coll. Cardiol., 51(7), 724–730 (2008).
   PubMed Web of Science ®Google Scholar
• Toth PP . Triglyceride-rich lipoproteins as a causal factor for cardiovascular disease. Vasc. Health Risk Manag., 12, 171–183 (2016).
   PubMed Web of Science ®Google Scholar
• Rapp JH , LespineA, HamiltonRLet al. Triglyceride-rich lipoproteins isolated by selected-affinity anti-apolipoprotein B immunosorption from human atherosclerotic plaque. Arterioscler. Thromb., 14(11), 1767–1774 (1994).
   PubMedGoogle Scholar
• Kugiyama K , DoiH, TakazoeKet al. Remnant lipoprotein levels in fasting serum predict coronary events in patients with coronary artery disease. Circulation, 99(22), 2858–2860 (1999).
   PubMed Web of Science ®Google Scholar
• Parhofer KG , ChapmanMJ, NordestgaardBG. Efficacy and safety of icosapent ethyl in hypertriglyceridaemia: a recap. Eur. Heart J. Suppl., 22(Suppl. J), J21–J33 (2020).
   PubMed Web of Science ®Google Scholar
• Jellinger PS , HandelsmanY, RosenblitPDet al. American Association of Clinical Endocrinologists and American College of Endocrinology guidelines for management of dyslipidemia and prevention of cardiovascular disease. Endocr. Pract., 23(Suppl. 2), 1–87 (2017).
   PubMed Web of Science ®Google Scholar
• Fan W , PhilipS, GranowitzC, TothPP, WongND. Prevalence of US adults with triglycerides ≥150 mg/dl: NHANES 2007–2014. Cardiol. Ther., 9(1), 207–213 (2020).
   PubMed Web of Science ®Google Scholar
• Fan W , PhilipS, GranowitzC, TothP, WongN. Hypertriglyceridemia in statin-treated US adults: The National Health and Nutrition Examination Survey. J. Clin. Lipidol., 13, 100–108 (2019).
   PubMed Web of Science ®Google Scholar
• Ganda OP , BhattDL, MasonRP, MillerM, BodenWE. Unmet need for adjunctive dyslipidemia therapy in hypertriglyderidemia management. J. Am. Coll. Cardiol., 72(3), 330–343 (2018).
   PubMed Web of Science ®Google Scholar
• Heymsfield SB , WaddenTA. Mechanisms, pathophysiology and management of obesity. N. Engl. J. Med., 376(3), 254–266 (2017).
   PubMed Web of Science ®Google Scholar
• Bhatt DL , StegG, MillerMet al. Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia. N. Engl. J. Med., 380(1), 11–22 (2019).
   PubMed Web of Science ®Google Scholar
• Bhatt DL , StegPG, MillerMet al. Effects of icosapent ethyl on total ischemic events: from REDUCE-IT. J. Am. Coll. Cardiol., 73(22), 2791–2802 (2019).
   PubMed Web of Science ®Google Scholar
• Toth PP , GranowitzC, HullM, LiassouD and ersonA, PhilipS. High triglycerides are associated with increased cardiovascular events, medical costs and resource utilization: a real-world administrative claims analysis of statin-treated patients with high residual cardiovascular risk. J. Am. Heart Assoc., 7(15), e008740 (2018).
   PubMed Web of Science ®Google Scholar
• Toth PP , PhilipS, HullM, GranowitzC. Association of elevated triglycerides with increased cardiovascular risk and direct costs in statin-treated patients. Mayo Clin. Proc., 94(9), 1670–1680 (2019).
   PubMed Web of Science ®Google Scholar
• Toth PP , GranowitzC, HullM and ersonA, PhilipS. Long-term statin persistence is poor among high-risk patients with dyslipidemia: a real-world administrative claims analysis. Lipids Health Dis., 18, 175 (2019).
   PubMed Web of Science ®Google Scholar
• Toth PP , PhilipS, HullM, GranowitzC. Elevated triglycerides (>/=150 mg/dl) and high triglycerides (200–499 mg/dl) are significant predictors of hospitalization for new-onset kidney disease: a real-world analysis of high-risk statin-treated patients. Cardiorenal Med., 9(6), 400–407 (2019).
   PubMed Web of Science ®Google Scholar
• Toth PP , PhilipS, HullM, GranowitzC. Elevated triglycerides (≥150 mg/dl) and high triglycerides (200–499 mg/dl) are significant predictors of new heart failure diagnosis: a real-world analysis of high-risk statin-treated patients. Vasc. Health Risk Manage, 15, 533–538 (2019).
   PubMed Web of Science ®Google Scholar
• Toth PP , PhilipS, HullM, GranowitzC. Hypertriglyceridemia is associated with an increased risk of peripheral arterial revascularization in high-risk statin-treated patients: a large administrative retrospective analysis. Clin. Cardiol., 42(10), 908–913 (2019).
   PubMed Web of Science ®Google Scholar
• Toth P , GranowitzC, PhilipS, LiassouD, AndersonA, HullM. Baseline characteristics of a retrospective claims analysis of cardiovascular outcomes and health care resource utilization and costs in high-risk statin-treated patients with hypertriglyceridemia. J. Clin. Lipidol., 11(3), 797 (2017).
   Google Scholar
• Vaziri ND . Dyslipidemia of chronic renal failure: the nature, mechanisms and potential consequences. Am. J. Physiol. Renal Physiol., 290(2), F262–F272 (2006).
   PubMed Web of Science ®Google Scholar
• Manjunath G , TighiouartH, IbrahimHet al. Level of kidney function as a risk factor for atherosclerotic cardiovascular outcomes in the community. J. Am. Coll. Cardiol., 41(1), 47–55 (2003).
   PubMed Web of Science ®Google Scholar
• Go AS , ChertowGM, FanD, McCullochCE, HsuCY. Chronic kidney disease and the risks of death, cardiovascular events and hospitalization. N. Engl. J. Med., 351(13), 1296–1305 (2004).
   PubMed Web of Science ®Google Scholar
• Lin J , KhetarpalSA, TerembulaK, ReillyMP, WilsonFP. Relation of atherogenic lipoproteins with estimated glomerular filtration rate decline: a longitudinal study. BMC Nephrol., 16, 130 (2015).
   PubMed Web of Science ®Google Scholar
• Toth P , GranowitzC, HullM, LiassouD and ersonA, PhilipS. Long-term renal function worsens in high cardiovascular risk patients with high triglycerides and well-controlled low-density lipoprotein cholesterol in a real-world analysis. J. Am. Coll. Cardiol., 71(Suppl. 11), A1445 (2018).
   Web of Science ®Google Scholar
• Banach M , StulcT, DentR, TothPP. Statin non-adherence and residual cardiovascular risk: there is need for substantial improvement. Int. J. Cardiol., 225, 184–196 (2016).
   PubMed Web of Science ®Google Scholar
• Toth PP , BanachM. Statins: then and now. Methodist Debakey Cardiovasc. J., 15(1), 23–31 (2019).
   PubMedGoogle Scholar
• Nichols GA , PhilipS, ReynoldsK, GranowitzCB, FazioS. Increased cardiovascular risk in hypertriglyceridemic patients with statin-controlled LDL cholesterol. J. Clin. Endocrinol. Metab., 103(8), 3019–3027 (2018).
   PubMed Web of Science ®Google Scholar
• Leatherman S , FergusonR, WeirIet al. Increased residual cardiovascular risk in US veterans and monerately-elevated baseline triglycerides and well-controlled LCL-C levels on statins. J. Am. Coll. Cardiol., 73(Suppl. 91)), 1719 (2019).
   PubMedGoogle Scholar
• Leatherman S , FergusonRE, HauCet al. Residual cardiovascular risk in U.S. veterans with moderately-elevated baseline triglycerides across the cardiovascular risk spectrum. J. Am. Coll. Cardiol., 75(1 Suppl. 11), 1980 (2020).
   Web of Science ®Google Scholar
• Nichols GA , PhilipS, ReynoldsK, GranowitzCB, FazioS. Increased residual cardiovascular risk in patients with diabetes and high vs. normal triglycerides despite statin-controlled LDL cholesterol. Diabetes Obes. Metab., 21(2), 366–371 (2019).
   PubMed Web of Science ®Google Scholar
• Nichols GA , PhilipS, ReynoldsK, GranowitzCB, O'Keefe-RosettiM, FazioS. Comparison of medical care utilization and costs among patients with statin-controlled low-density lipoprotein cholesterol with versus without hypertriglyceridemia. Am. J. Cardiol., 122(7), 1128–1132 (2018).
   PubMed Web of Science ®Google Scholar
• Bhatt DL , StegG, MillerMet al. Effects of icosapent ethyl on total ischemic events: from REDUCE-IT. J. Am. Coll. Cardiol., 73(22), 2791–2802 (2019).
   PubMed Web of Science ®Google Scholar
• Peterson BE , BhattDL, StegGet al. Reduction of revascularization in patients with hypertriglyceridemia with icosapent ethyl: insights from REDUCE-IT REVASC [oral presentation]. Presented at: Annual Scientific Sessions of the Society for Cardiovascular Angiography and Interventions. ( virtual) (15 May 2020).
   Google Scholar
• Dorais M , ChirovskyD, AmbegaonkarBet al. Utilization patterns of extended-release niacin in Canada: analysis of an administrative claims database. Can. J. Cardiol., 26(7), e229–e235 (2010).
   PubMed Web of Science ®Google Scholar
• Virani SS , AkeroydJM, NambiVet al. Estimation of eligibility for proprotein convertase subtilisin/kexin type 9 inhibitors and associated costs based on the FOURIER trial (Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk): insights from the Department of Veterans Affairs. Circulation, 135(25), 2572–2574 (2017).
   PubMed Web of Science ®Google Scholar
• Colantonio LD , HuangL, MondaKLet al. Adherence to high-intensity statins following a myocardial infarction hospitalization among Medicare beneficiaries. JAMA Cardiol., 2(8), 890–895 (2017).
   PubMed Web of Science ®Google Scholar
• Deshpande S , QuekRG, ForbesCAet al. A systematic review to assess adherence and persistence with statins. Curr. Med. Res. Opin., 33(4), 769–778 (2017).
   PubMed Web of Science ®Google Scholar
• Ofori-Asenso R , IlomakiJ, TaceyMet al. Patterns of statin use and long-term adherence and persistence among older adults with diabetes. J. Diabetes, 10(9), 699–707 (2018).
   PubMed Web of Science ®Google Scholar
• Shroufi A , PowlesJW. Adherence and chemoprevention in major cardiovascular disease: a simulation study of the benefits of additional use of statins. J. Epidemiol. Community Health, 64(2), 109–113 (2010).
   PubMed Web of Science ®Google Scholar
• American Diabetes Association . Cardiovascular disease and risk management: standards of medical care in diabetes-2020. Diabetes Care, 43(Suppl. 1), S111–S134 (2020).
   PubMedGoogle Scholar
• Orringer CE , JacobsonTA, MakiKC. National Lipid Association Scientific Statement on the use of icosapent ethyl in statin-treated patients with elevated triglycerides and high or very-high ASCVD risk. J. Clin. Lipidol., 13(6), 860–872 (2019).
   PubMed Web of Science ®Google Scholar
• Mach F , BaigentC, CatapanoALet al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS). Eur. Heart J., 41(1), 111–188 (2020).
   PubMed Web of Science ®Google Scholar